Patient outcomes and clinical characteristics of ATTR-CM patients treated with tafamidis: A single center experience in Turkey - Study ATTREAL

Study identification

• EU PAS number:
  EUPAS1000000561
• Study ID:
  1000000561
• Official title and acronym:
  Patient outcomes and clinical characteristics of ATTR-CM patients treated with tafamidis: A single center experience in Turkey - Study ATTREAL
• DARWIN EU® study:
  No
• Study countries:
  Türkiye
• Study description:
  The aim of this study is to describe the clinical characteristics and outcomes of patients with ATTR amyloid cardiomyopathy (ATTR-CM) treated with tafamidis at a single center in Turkey.
• Study status:
  Planned

Research institutions and networks

Institutions

Pfizer

Study timelines

Date when funding contract was signed

Planned: 07/01/2025

Actual: 07/01/2025

Study start date

Planned: 29/08/2025

Date of final study report

Planned: 28/02/2026

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

B3461126